If you wish to re-publish this story please do so with following accreditation
EDITOR: Heather Allman
PUBLISHER: CANNABIS LAW REPORT
Biopharmaceutical Research Company (BRC) Will Be Among First in the Nation to Receive a License for Federal Cannabis Production
Biopharmaceutical Research Company (BRC), a specialty pharmaceutical manufacturing and analytical company focused on plant-based therapeutics, will soon be awarded one of the first federal production licenses from the Drug Enforcement Administration (DEA) to produce clean, consistent and compliant cannabis for federally approved researchers across the United States.
BRC will be among a select few organizations to receive such a license after the DEA amended regulations within the Controlled Substances Act to begin allowing the cultivation of cannabis for research purposes.
Prior to this May 14, 2021 decision by the DEA, only one facility in the United States was federally authorized to cultivate cannabis for research purposes.
“Once finalized, this federal license will forever change the trajectory of our business and the medicinal cannabis industry. The DEA’s leadership will set off a nationwide wave of innovative cannabis-derived treatments, unlock valuable intellectual property and create high quality American jobs,” said BRC CEO George Hodgin, a former US Navy SEAL.
“The BRC team is already familiar with DEA compliance procedures based on our extensive history of controlled substances activity, and our world class staff is ready to hit the ground running on this new business arm that the DEA has authorized.
Cultivation and compliance are our bread and butter, and now that we are in a position to receive this license, our best work yet can begin to take shape.”
BRC is already certified by the DEA and United States Department of Agriculture (USDA) to analyze and test controlled substances, including cannabis and hemp.
“We have invested a great deal of money and waited a very long time for this over the last four years, and this is the validation and the holy grail we’ve been waiting for,” added Hodgin:
“With this license, BRC can legally produce quality cannabis and cannabis-derived products that can be used to identify new treatments that can help veterans and all patients struggling with chronic pain, cancer, and countless other illnesses. Equally important, we will also gain valuable insights into the potential dangers and misuse associated with cannabis that will help keep all Americans safe and healthy.
We are proud and honored to be one of the first federally legal cannabis companies in the United States.”
George Hodgin is a graduate of the Stanford Graduate School of Business, a former Navy SEAL and the CEO of Biopharmaceutical Research Company near Monterey, CA.
About Biopharmaceutical Research Company
BRC is a specialty pharmaceutical company that holds several DEA Registrations and is pioneering the federally legal cannabis space in the USA. BRC also conducts federally compliant cannabis-specific analytical activities.